Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Gastrointestinal Neoplasms 1Disease Progression 1Digestive System Neoplasms 1Carcinoma in Situ 1Advanced Malignant Solid Tumors 1

Interventions

pembrolizumab 20Gemcitabine 18Cisplatin 14Magnetic Resonance Spectroscopy 13enfortumab vedotin 12Specimen Handling 10Cystectomy 10Docetaxel 8Mitomycin 7Standard of Care 6Cystoscopy 6Transurethral Resection of Bladder 5Radiotherapy 5Carboplatin 5durvalumab 4Practice Guidelines as Topic 4Nivolumab 4Radiation 3Multiparametric Magnetic Resonance Imaging 3Mitozytrex 3Fluorouracil 3tislelizumab 2dehydroftorafur 2cemiplimab 2avelumab 2alvimopan 2Therapeutics 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Urinary Bladder Neoplasms × Clinical Trials, Phase II as Topic × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06364956 2025-08-11

Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2 Recruiting
36 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡